Cost-Minimization and Budget Impact Analysis of Rituximab SC VS Rituximab IV for Non-Hodgkin’s Lymphoma (NHLs) in Greece

ISSN Print: 2151-1934
ISSN Online: 2151-1942
www.scirp.net/journal/jct
E-mail: [email protected]

Citations

"Cost-Minimization and Budget Impact Analysis of Rituximab SC VS Rituximab IV for Non-Hodgkin’s Lymphoma (NHLs) in Greece"
written by Dionysis Kyriopoulos, Vasiliki Tsiantou, Labrini Papageorgiou, Fani Theodoropoulou, Kostas Athanasakis,
published by Journal of Cancer Therapy, Vol.8 No.8, 2017

has been cited by the following article(s):

[1]	Pharmaceutical and biotech industry perspectives on optimizing patient experience and treatment adherence through subcutaneous drug delivery design
	Advanced Drug Delivery …, 2024

[2]	Subcutaneous Delivery of High-Dose/Volume Biologics: Current Status and Prospect for Future Advancements
	2021

[3]	Accelerating the development of novel technologies and tools for the subcutaneous delivery of biotherapeutics
	2020

[4]	SAĞLIK SEKTÖRÜNDE BÜTÇE ETKİ ANALİZİ
	2018

[5]	Sağlık Sektöründe Bütçe Etki Analizi
	2018

[6]	Injection technique 2: administering drugs via the subcutaneous route
	Â Nursing TimesÂ [online], 2018